February 28, 2018

Solid Honors Rare Disease Day 2018

Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day, which takes place annually on February 28th. Rare Disease Day seeks to raise awareness of the current challenges faced by patients living with rare diseases. The campaign is spearheaded by the European Organisation for Rare Diseases (EURORDIS) and is observed globally.

As a company solely focused on Duchenne muscular dystrophy (DMD), Solid was honored to host several families with DMD, who shared their personal stories of living with this rare disease and educated our employees about DMD. It is their courage and drive that continue to inspire us in our important work every day. 

Rare Disease Day 2018

Related news

Jun18

We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.

Jun18

- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway

- Conference Call Scheduled for Today at 8:30 A.M. ET

May19

- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -

- Company Continues to Advance Gene Therapy Portfolio -

May10
Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial
Apr18

Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial

Apr18

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -

Mar29

Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.

Mar14

Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.

Mar14

Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.

Nov30

Today we are excited to announce the initiation of our first clinical trial for SGT-001.

Pages

More information about Solid?

Please subscribe to receive our latest news